#EXEL

4 months ago

#EXEL Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/EXEL/exelixis-annou...

0 0 0 0

Exelixis Q2 Revenue Falls 11 Percent | The Motley Fool

7 months ago

#EXEL #b0892242-3616-4350-b54a-cf8ab419e03a #data-news

Origin | Interest | Match

0 0 0 0

Exelixis Earnings Report: Record $520M Cabozantinib Sales Drive Growth as NET Launch Shows Early Success Q2 results reveal $568.3M revenue, positive STELLAR-303 trial results, and NET approval in EU. Strong Cabozantinib performance drives growth. See full details.

7 months ago

#EXEL Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/EXEL/exelixis-annou...

0 0 0 0

8 months ago

#PFE #EXEL #689ca4cf-6aa8-49f3-a43f-22abbeb24639 #investing

Origin | Interest | Match

0 0 0 0

Dinero en USA 🇺🇸🪙

@dineroenusa.com

8 months ago

3/ EMPRESAS EN MOVIMIENTO 🔄

#Tesla: +8% tras comentarios positivos de Musk sobre el lanzamiento del robotaxi #TSLA

#EXEL sube con fuerza tras resultados positivos de su medicamento contra cáncer colorrectal

Hims: -30% después que #NVO terminara su colaboración #HIMS

0 0 1 0

9 months ago

www.fool.com/investing/2025/05/30/2-t...

#NVO #EXEL #c435576d-a523-43a8-8d2c-e417dd41608c #investing

Result Details

0 0 0 0

InsiderFinance

@insiderfinance.com

9 months ago

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GOOG, #U, #LYFT, #MNST, #EXEL

#OptionFlow #OptionsTrading #Trading

0 0 0 0

10 months ago

www.fool.com/investing/2025/05/14/why...

#EXEL #32ea020a-5366-479e-bafe-d86fc8372b8b #investing

Result Details

0 0 0 0

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update Exelixis (NASDAQ: EXEL) reported strong Q1 2025 financial results with total revenues of $555.4M, up from $425.2M in Q1 2024. The company's CABOMETYX franchise generated $513.3M in U.S. net product revenues. GAAP diluted EPS reached $0.55, while non-GAAP diluted EPS was $0.62. Following strong performance, Exelixis increased its 2025 guidance by $100M for both net product revenues and total revenues. Key highlights include FDA approval for CABOMETYX in advanced neuroendocrine tumors (NET) and promising developments in the zanzalintinib pipeline. The company continues its stock repurchase program, having bought back $494.5M worth of shares at an average price of $34.87 per share.

10 months ago

#EXEL Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/EXEL/exelixis-annou...

0 0 0 0

Can Exelixis' Massive New $500M Buyback Signal Even Bigger Returns Ahead? Fourth buyback program since 2023 brings total shareholder returns to $1.7B, demonstrating strong cash position and commitment to strategic capital deployment

1 year ago

#EXEL Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

www.stocktitan.net/news/EXEL/exelixis-annou...

0 0 0 0

Exelixis Crushes Earnings Estimates: Cancer Drug Sales Drive Record $2.17B Revenue Year Exelixis reports robust Q4 with $567M revenue, strong cabozantinib sales of $515M, and raises full-year EPS to $1.76. FDA decision pending for key expansion.

1 year ago

#EXEL Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/EXEL/exelixis-annou...

0 0 0 0

Exelixis Sets Date for Major 2024 Performance Reveal: Key Details Inside Exelixis schedules Q4 and FY2024 earnings release for February 11, followed by management conference call and webcast to discuss results and provide corporate updates.

1 year ago

#EXEL Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

www.stocktitan.net/news/EXEL/exelixis-to-re...

0 0 0 0

Exelixis Reports Strong $1.8B Revenue for 2024, Projects Growth in 2025 with New Cancer Drug Expansion Exelixis achieves $1.805B in cabozantinib franchise revenue for 2024, forecasts up to $2.05B for 2025. Awaiting FDA approval for NET indication with April deadline.

1 year ago

#EXEL Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

www.stocktitan.net/news/EXEL/exelixis-annou...

0 0 0 0